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Purpose: To compare the effect of early versus late intravitreal injection of triamcinolone in patients with 
macular edema due to branch retinal vein occlusion (BRVO). 
Methods: Twenty eyes of 20 patients with macular edema from BRVO, including 10 with duration after 
onset of ≤3 months and 10 with duration of >3 months, were treated using a single intravitreal 
triamcinolone injection (4 mg/0.1 ml). Best-corrected visual acuity and foveal thickness by optical coherence 
tomography were measured 1, 3, and 6 months post-injection. 
Results: In patients that received treatment after a disease duration of ≤3 months, visual acuity and foveal 
thickness significantly improved from baseline over 6 months of follow-up. However, in those with a duration 
of > 3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not 
maintained at 3 and 6 months post-triamcinolone.
Conclusions: Intravitreal triamcinolone is more effective in patients with BRVO who are treated earlier. 
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A few studies on patients with branch retinal vein 
occlusion (BRVO) have suggested that intravitreal corticosteroid 
can reduce macular edema and increase visual acuity.
1-3 
However, these studies did not evaluate the effectiveness of 
triamcinolone with respect to the timing of the intravitreal 
injection. In addition, follow-up periods were inadequate or 
patients who had undergone multiple injections of intravitreal 
triamcinolone or combined treatment with laser photo- 
coagulation were included. The purpose of this study was to 
directly compare the effect of an early versus a late 
intravitreal triamcinolone as a primary treatment for macular 
edema due to BRVO.
Patients and Methods
This study had been performed according to the Declaration 
of Helsinki of the World Medical Association. This 
retrospective study included 20 eyes of 20 patients who 
received a single injection of intravitreal triamcinolone (4 
mg/0.1 ml) as an only treatment for macular edema from 
BRVO between July 2004 and June 2005, and who had a 
post-injection follow-up time of >6 months. Of these 20 
patients, 10 had a disease duration from onset to injection of 
≤3 months and the other 10 had a duration of >3 months. 
We designated these as the early treatment and late treatment 
groups, respectively. Best-corrected Snellen visual acuity 
(converted to logarithms of the minimal angle of resolution 
[logMAR]), intraocular pressure (IOP) by Goldmann 
applanation tonometry, and foveal thickness on optical 
coherence tomography (Stratus OCT
TM; Carl Zeiss Meditec 
Inc., Dublin, CA, USA) were measured at baseline and at 1, 
3, and 6 months post-injection. The difference between 
baseline and postoperative measurements in logMAR visual 
acuity and foveal thickness were compared in each group, 
using the two-tailed Student's t test and the chi-square test. 
Statistical significance was accepted at p<0.05.
The protocol was approved by the Institutional Review 
Board of Seoul National University Hospital, Seoul, Korea, JY Oh, et al. INTRAVITREAL TRIAMCINOLONE FOR MACULAR EDEMA
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Fig. 1. LogMAR visual acuity results in the early and late 
treatment groups. A significant sustained improvement was 
evident in the early treatment group throughout the subsequent 
6-month follow-up, but in the late treatment group, the initial 
improvement at 1 month was not sustained at 3 and 6 months.
Characteristics Early treatment group Late treatment group P value
No. of eyes 10 10 -
Age (years) 59.7±1.0 57.5±5.1 0.663
Sex (male/female) 4/6 5/5 0.893
Laterality (left/right) 3/7 4/6 0.734
Lens status (phakia/pseudophakia) 9/1 9/1 -
Visual acuity (LogMAR) 1.07±0.45 0.80±0.45 0.087
Duration from onset to injection (months) 1.0±0.2 5.1±1.1 <0.001
Location of vein occlusion (ST/IT
*) 5/5 6/4 0.893
Area of vein occlusion (DA
†) 6.9±3.7 7.1±4.0 0.253
Thickness of the fovea  666.8±291.7μm 597.3±180.1μm0 . 0 9 2
* ST : Superotemporal, IT : Inferotemporal. 
†DA : Disc area.
Table 1. Patient demographics and characteristics of the retinal vein occlusion in the early and late treatment 
groups
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Fig. 2. Foveal thickness by optical coherence tomography in the 
early and late treatment groups. A significant improvement was
observed in the early treatment group throughout the 6-month 
follow-up, but the improvement observed at 1month was not 
further sustained in the late treatment group. 
and informed consent was obtained from the patients. 
Results
Patient demographics and characteristics of BRVO are 
shown in Table 1; no statistically significant differences were 
found between the two groups. In the early treatment group, 
mean visual acuity significantly improved from a baseline of 
1.07±0.45 logMAR units to 0.74±0.51 (p=0.021) at 1 
month, 0.63±0.43 (p=0.012) at 3 months, and 0.34±0.33 
(p=0.005) at 6 months post-injection. In this group, mean 
foveal thickness was 666.8±291.7 μm at baseline, and 
significantly reduced to 233.8±77.2 μm (p<0.001) at 1 
month, 351.1±180.8 μm (p=0.026) at 3 months, and 446.2±
266.6  μm (p=0.029) at 6 months. However, in the late 
treatment group, though mean visual acuity significantly 
improved from baseline 0.80±0.45 to 0.47±0.37 (p=0.039) 
at 1 month, it did not further improve at 3 months (0.54±
0.34, p=0.080) or 6 months (0.60±0.53, p=0.226). Similarly, 
mean foveal thickness decreased significantly from baseline 
597.3±180.1μm to 344.0±183.3 μm (p=0.030) at 1 month, 
but results did not significantly improve at 3 months (464.0
±246.8  μm, p=0.594) or 6 months (545.1±204.6 μm, 
p=0.952). Comparisons of mean visual acuity and foveal 
thickness in the two groups are shown in figures 1 and 2, 
respectively. One patient in the early treatment group and two 
in the late treatment group experienced an elevated IOP 
during follow-up, and one in the late treatment group 
required trabeculectomy.Kor J Ophthalmol Vol.21, No.1, 2007
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Discussion
The macular edema due to BRVO may ultimately 
disappear because the collateral circulation usually bypasses 
the blockage over a period of 6 to 24 months after BRVO 
onset.
4 However, vision may not improve due to retinal 
pigment epithelium atrophy, even after the disappearance of 
macular edema, and thus, an early reduction in macular 
edema is important if vision is to be restored. Triamcinolone 
might control macular edema while the collateral circulation 
is established in BRVO,
5 and result in a visual improvement. 
Our study shows that patients with macular edema from 
BRVO responded to intravitreal injection of triamcinolone 
with regard to foveal thickness and visual acuity with the 
group of a short disease duration showing a greater response. 
Patients with a disease duration of >3 months did not sustain 
foveal thickness and visual acuity improvements through a 
6-month follow-up, whereas those with a duration of ≤3 
months showed continued improvements through follow-up.
The present study has the major limitation that follow-up 
was conducted over only 6 months. It is possible that the 
effect of triamcinolone would reduce in the early treatment 
group with time, because foveal thickness of both groups was 
increasing after the post-injection one month, while visual 
acuity was still improving in the early treatment group at the 
post-injection 6 months. 
Thus, further investigation with a longer follow-up is 
necessary to better ascertain the long-term effect of 
intravitreal triamcinolone on the degree of macular edema 
and visual outcome with respect to disease duration. In 
conclusion, we find that intravitreal triamcinolone is more 
effective over a 6 month period in BRVO patients who are 
treated earlier.
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